Trisalus Life Sciences, Inc. (TLSI) fundamentals score
Trisalus Life Sciences is a growing, oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 ("TRL9") agonist, for a range of different therapeutic and technology applications.
Surgical & Medical Instruments & Apparatus · Healthcare · Listed on NASDAQ
Overall: 4.8 out of 10, Weak long-term fundamentals
- Growth: 4.0/10
- Profitability: 4.2/10
- Financial health: 4.8/10
- Earnings quality: 7.0/10
- Valuation: 4.7/10
Scores are calculated from Trisalus Life Sciences, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10